News | Biogen

June 17, 2021

Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study

Global Phase 3 TOPAZ-1 study will evaluate the efficacy and safety of BIIB059, as compared to placebo, in active systemic lupus erythematosus (SLE) , a debilitating autoimmune disease which has limited treatment options Positive Phase 2 LILAC study efficacy results support the further evaluation of

June 16, 2021

Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease

June 15, 2021

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

Grid View List View

March 30, 2020

Biogen to Webcast Encore Aducanumab Presentation From Virtual AAT-AD/PD Meeting on April 2, 2020

Cambridge, Mass. – March 30, 2020 – Biogen (Nasdaq: BIIB) today announced it will host a webcast of its encore presentation related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming virtual AAT-AD/PDTM focus meeting. The data in this presentation were previously

March 16, 2020

Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World

Most of the funds will be directed to support the global response and the immediate needs of communities hardest hit by COVID-19 CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Biogen Inc . (Nasdaq: BIIB) today announced that the Biogen Foundation has committed $10 million to support global

February 27, 2020

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases

Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a neuromuscular target, with exclusive rights for nine additional undisclosed

February 24, 2020

Biogen to Present at the Cowen 40th Annual Health Care Conference

Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that it will present at the Cowen 40th Annual Health Care Conference. The webcast will be live on Monday, March 2, at 11:20 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors .

January 13, 2020

Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.

PF-05251749 is a CNS-penetrant regulator of circadian rhythm with potential to address behavioral and neurological symptoms across various psychiatric and neurological diseases Biogen to pay Pfizer $75 million upfront plus potential milestones of up to $635 million, and royalties PF-05251749

December 18, 2019

Biogen to Report Fourth Quarter and Year-End 2019 Financial Results January 30, 2020

Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) today announced it will report fourth quarter and year-end 2019 financial results Thursday, January 30, 2020, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at

December 17, 2019

Biogen to Present at the 38th Annual J.P. Morgan Healthcare Conference

Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 13, 2020 at 3:30 p.m. PT, 6:30 p.m. ET. To access the live webcast, please visit Biogen’s Investors section at

December 13, 2019

Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy

The primary endpoint of the Phase 2 PASSPORT study was not met, and further development of gosuranemab in progressive supranuclear palsy (PSP) will not be pursued CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Today, Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 2

December 3, 2019

Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)

The Phase 2 LILAC study met its primary endpoints, demonstrating statistically significant reduction of disease activity in patients with CLE and SLE who received BIIB059 compared to placebo Positive results support Biogen’s goal of building a multi-franchise portfolio and underscore the company’s

November 22, 2019

Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)

CAMBRIDGE, Mass., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced detailed results from the Phase 3 EVOLVE-MS-2 study demonstrating the improved patient-assessed gastrointestinal (GI) tolerability of VUMERITY™ (diroximel fumarate), a new FDA-approved treatment for